Last reviewed · How we verify
Ivabradine + Usual Care
Ivabradine selectively inhibits the funny current (If) in the sinoatrial node to reduce heart rate without affecting blood pressure or contractility.
Ivabradine selectively inhibits the funny current (If) in the sinoatrial node to reduce heart rate without affecting blood pressure or contractility. Used for Heart failure with reduced ejection fraction (HFrEF) in combination with standard therapy, Symptomatic chronic heart failure.
At a glance
| Generic name | Ivabradine + Usual Care |
|---|---|
| Sponsor | The University of Hong Kong |
| Drug class | If channel inhibitor |
| Target | HCN (hyperpolarization-activated cyclic nucleotide-gated channel) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ivabradine works by blocking the hyperpolarization-activated cyclic nucleotide-gated channel (HCN) that mediates the funny current, which is responsible for diastolic depolarization in pacemaker cells. This selective heart rate reduction improves myocardial oxygen supply-demand balance in heart failure patients. The combination with usual care aims to provide additive symptomatic and potentially prognostic benefits in heart failure management.
Approved indications
- Heart failure with reduced ejection fraction (HFrEF) in combination with standard therapy
- Symptomatic chronic heart failure
Common side effects
- Bradycardia
- Visual disturbances (luminopsia)
- Phosphenes
- Atrial fibrillation
- Dizziness
Key clinical trials
- RECOVER-AUTONOMIC Platform Protocol (PHASE2)
- RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) (PHASE2)
- Atrial Fibrillation: In Search for the Optimal Target for Rate Control (PHASE4)
- LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB (NA)
- Ivabradine to Prevent Anthracycline-induced Cardiotoxicity (PHASE3)
- Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ivabradine + Usual Care CI brief — competitive landscape report
- Ivabradine + Usual Care updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI